HSPA12B and stroke disorder: Interestingly, administration with L‐NAME significantly decreased mice survival within 28 days post‐stroke in HSPA12B Tg mice compared with HSPA12B Tg mice that without L‐NAME administration (P < 0.05; Fig. 8).